Holen Sie sich die Stockscreener-App
3.92
91.22%
1.87
Handel nachbörslich:
3.99
0.07
+1.79%
Schlusskurs vom Vortag:
$2.05
Offen:
$2.96
24-Stunden-Volumen:
82.79M
Relative Volume:
37.38
Marktkapitalisierung:
$193.22M
Einnahmen:
$42,000
Nettoeinkommen (Verlust:
$-12.38M
KGV:
-14.88
EPS:
-0.2634
Netto-Cashflow:
$-9.61M
1W Leistung:
+96.98%
1M Leistung:
+140.49%
6M Leistung:
+152.90%
1J Leistung:
+110.75%
1-Tages-Spanne:
$2.77
$4.20
1-Wochen-Bereich:
$1.9101
$4.20
52-Wochen-Spanne:
$0.91
$4.20
Entera Bio Ltd Stock (ENTX) Company Profile
Firmenname
Entera Bio Ltd
Sektor
Branche
Telefon
972-2-532-7151
Adresse
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
3.92 | 101.04M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-22 | Eingeleitet | Aegis Capital | Buy |
Entera Bio Ltd Aktie (ENTX) Neueste Nachrichten
Entera Bio Ltd. announced that it expects to receive $274.999977 million in funding from a group of investors - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entera Bio raises $275m for Phase III osteoporosis drug trialGlobes - Globes - Israel Business News
Entera Bio raises $275 million in private placement for phase 3 - Investing.com
ENTX Stock Explodes Higher As Traders Pounce On Breakout - StocksToTrade
Entera Bio stock surges on $275M private placement - Investing.com
Entera Bio raises $275 million in private placement - Investing.com
Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement - TradingView
Entera Bio raises $275 million in private placement By Investing.com - Investing.com Canada
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement - GlobeNewswire
ENTX|Entera Bio Ltd|Price:3.930|Chg%:+1.880 - TradingKey
Entera Bio Ltd (ENTX) Cash Flow - TradingKey
Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entera Bio Ltd (ENTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ENTX|Entera Bio Ltd|Price:3.830|Chg%:+1.780 - TradingKey
ENTX|Entera Bio Ltd|Price:2.050|Chg%:-0.080 - TradingKey
Entera Bio Ltd (ENTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entera Bio Leads Our Top 3 Penny Stocks To Consider - Sahm
Entera Bio Ltd. (ENTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know - Yahoo Finance
Entera Bio Expands Share Authorization and Equity Plans - TipRanks
Entera Bio Ltd. Approves Director Compensation, Share-Based Plans, and Capital Increase at 2026 Annual Meeting - Minichart
Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool - Stock Titan
Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs - Stock Titan
Entera Bio shareholders approve authorized share increase at annual meeting - Bitget
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - TipRanks
After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - Benzinga
Entera Bio (ENTX) Slips Slightly as Stock Hovers Near Key Support LevelLast Point Resistance - dars.gov.et
America’s Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) - TipRanks
America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) - Benzinga
ENTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseEarnings Volatility Report - dars.gov.et
Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus - TradingView
Price to earnings forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to earnings forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to EBIT forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Price to book forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Entera Bio Ltd. Actuals & Estimates (HAM:5DT) - TradingView
ENTX Forecast — Price Target — Prediction for 2027 - TradingView
5DT Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback - Investing.com UK
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewswire Inc.
Finanzdaten der Entera Bio Ltd-Aktie (ENTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):